A comparative study of simvastatin and atorvastatin on contrast induced nephropathy in patients with coronary heart disease and diabetes mellitus during perioperative period of PCI

Xiaoye Li,Qibing Wang,Yanan Hu,Qianzhou Lyu

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2016.21.006

2016-01-01

Abstract:Objective To investigate simvastatin and atorvastatin for contrast-induced nephropathy (CIN) prevention after coronary angiography or percutaneous coronary intervention (PCI) in patients with coronary heart disease and diabetes mellitus.Methods The research was non-randomized concurrent controlled study. We enrolled the diabetics who were underwent percutaneous coronary intervention in the department of cardiovascular from January 2015 to December 2015. The baseline characteristics of all patients and the rate of hospitalization within one month were collected. The primary end point of the study was the incidence of CIN of the two groups. The secondary end point was the rate of re-hospitalization within one month including the cardiovascular and cerebrovascular disease, heart failure, and the rate of revascularization and the safety evaluation of statin medication.Results 211 patients with coronary heart disease complicated with diabetes were enrolled in this study. 83 patients were enrolled in the observation group (simvastatin 40 mg) and 128 patients were enrolled in the control group (atorvastatin 40 mg). In the control group, the levels of total cholesterol and low density lipoprotein were higher than the observation group [(1.99±0.96)mmol/Lvs. (1.79±0.74)mmol/L,P=0.039; (3.81±1.10)mmol/Lvs. (3.58±0.79)mmol/L, P=0.009, respectively]. Overall, 21 (9.95%) patients were developed into CIN according to the definition of an increase of 25% of pre-Scr. 11 cases (13.2%) in the observation group were developed into CIN, while there were 10 cases (7.8%) in the control group. There was no significance with the rate of CIN between the two groups (P=0.197). With the high risk CIN patients, there was no significant difference between the two groups. No significance was found in the re-hospitalization rate and creatine kinase-MM of the observation group and observation group within one-month follow-up [15.6%vs. 15.6%,P=0.994; (83.7±62.8)U/Lvs. (81.6±59.0)U/L,P=0.581, respectively].Conclusion Simvastatin (40 mg) could not decrease the rate of CIN in coronary heart disease with diabetes compared with atorvastatin (20 mg).